Xu, Qun; Li, Tian; Chen, Hekai; Kong, Jun; Zhang, Liwei; Yin, Hang published an article in 2021. The article was titled 《Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy》, and you may find the article in RSC Medicinal Chemistry.COA of Formula: C6H7Br2N The information in the text is summarized as follows:
A small-mol. co-inhibitor that targets the TLR2/4 signalling pathway were developed. After high-throughput screening of a compound library containing 14400 small mols., followed by hit-to-lead structural optimization, the compound I was finally obtained, which has effective inhibitory properties against the TLR2/4 signalling pathways. This compound was found to significantly inhibit multiple pro-inflammatory cytokines released by RAW264.7 cells. This was followed by compound I demonstrating promising efficacy in subsequent anti-tumor experiments The current results provided a novel understanding of the role of TLR2/4 in cancer and a novel strategy for anti-tumor therapy. After reading the article, we found that the author used 2-(Bromomethyl)pyridine hydrobromide(cas: 31106-82-8COA of Formula: C6H7Br2N)
2-(Bromomethyl)pyridine hydrobromide(cas: 31106-82-8) belongs to pyridine. When pyridine is adsorbed on oxide surfaces or in porous materials, the following species are commonly observed: (i) pyridine coordinated to Lewis acid sites, (ii) pyridine H-bonded to weakly acidic hydroxyls, and (iii) protonated pyridine. At high coverage, physisorbed pyridine and protonated dimers can also be observed.COA of Formula: C6H7Br2N